![Gavin Xia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gavin Xia
Keine laufenden Positionen mehr
Vermögen: 301 Mio $ am 30.06.2026
Profil
Dr. Gavin Xia is a Chief Executive Officer at Alebund Pharmaceuticals (Jiangsu) Ltd., a Chief Executive Officer at Shanghai Alebund Pharmaceutical Technology Co., Ltd. and a Venture Partner at LAV Management Co., Ltd. Dr. Xia was previously employed as a Non-Executive Director by Abbisko Cayman Ltd. and a Non-Executive Director by Abbisko Therapeutics Co., Ltd. He also served on the board at Shanghai Kun Yuan Biotechnology Co. Ltd. and Beijing Jiakesi New Drug Development Co. Ltd. He received his undergraduate degree from Peking University and a doctorate degree from The University of Chicago.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
11,33 % | 29.06.2026 | 32 069 014 ( 11,33 % ) | 188 Mio $ | 30.06.2026 |
8,54 % | 29.06.2026 | 19 401 461 ( 8,54 % ) | 114 Mio $ | 30.06.2026 |
Aktive Positionen von Gavin Xia
| Unternehmen | Position | Beginn |
|---|---|---|
LAV Management Co., Ltd.
 LAV Management Co., Ltd. Investment ManagersFinance LAV invests in companies located in China and the United States. The firm targets companies operating in the fields of biopharmaceuticals, human therapeutics, medical devices and diagnostics. It provides financing for seed, early and later stage capital requirements. | Private Equity Investor | - |
Shanghai Alebund Pharmaceutical Technology Co., Ltd.
 Shanghai Alebund Pharmaceutical Technology Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company, focuses on novel therapies discovery and development for kidney diseases | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Gavin Xia
| Unternehmen | Position | Ende |
|---|---|---|
| ABBISKO CAYMAN LIMITED | Direktor/Vorstandsmitglied | 19.06.2023 |
Shanghai Kun Yuan Biotechnology Co. Ltd. | Direktor/Vorstandsmitglied | 01.02.2021 |
Beijing Jiakesi New Drug Development Co. Ltd.
 Beijing Jiakesi New Drug Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops and sells drugs | Direktor/Vorstandsmitglied | - |
Abbisko Therapeutics Co., Ltd.
 Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Researches and develops biomedicine and biotechnology | Direktor/Vorstandsmitglied | - |
Ausbildung von Gavin Xia
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
99
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Peking University
 Peking University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Chicago
 The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LAV Management Co., Ltd.
LAV Management Co., Ltd. Investment ManagersFinance LAV invests in companies located in China and the United States. The firm targets companies operating in the fields of biopharmaceuticals, human therapeutics, medical devices and diagnostics. It provides financing for seed, early and later stage capital requirements. | Finance |
Abbisko Therapeutics Co., Ltd.
Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Researches and develops biomedicine and biotechnology | Health Technology |
Beijing Jiakesi New Drug Development Co. Ltd.
Beijing Jiakesi New Drug Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops and sells drugs | Health Technology |
Shanghai Alebund Pharmaceutical Technology Co., Ltd.
Shanghai Alebund Pharmaceutical Technology Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company, focuses on novel therapies discovery and development for kidney diseases | Health Technology |
Abbisko Cayman Ltd.
 Abbisko Cayman Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule oncology therapies | Health Technology |
Shanghai Kun Yuan Biotechnology Co. Ltd. |
